316 related articles for article (PubMed ID: 26741884)
21. The leukotriene B4 paradox: neutrophils can, but will not, respond to ligand-receptor interactions by forming leukotriene B4 or its omega-metabolites.
Haines KA; Giedd KN; Rich AM; Korchak HM; Weissmann G
Biochem J; 1987 Jan; 241(1):55-62. PubMed ID: 3032161
[TBL] [Abstract][Full Text] [Related]
22. Effect of structural modification at carbon atom 1 of leukotriene B4 on the chemotactic and metabolic response of human neutrophils.
Clancy RM; Dahinden CA; Hugli TE
Anal Biochem; 1987 Mar; 161(2):550-8. PubMed ID: 3034102
[TBL] [Abstract][Full Text] [Related]
23. 15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils.
Ternowitz T; Fogh K; Kragballe K
Skin Pharmacol; 1988; 1(2):93-9. PubMed ID: 2856182
[TBL] [Abstract][Full Text] [Related]
24. Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982.
Jackson WT; Boyd RJ; Froelich LL; Mallett BE; Gapinski DM
J Pharmacol Exp Ther; 1992 Dec; 263(3):1009-14. PubMed ID: 1335049
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cytoskeletal rearrangement by botulinum C2 toxin amplifies ligand-evoked lipid mediator generation in human neutrophils.
Grimminger F; Sibelius U; Aktories K; Suttorp N; Seeger W
Mol Pharmacol; 1991 Oct; 40(4):563-71. PubMed ID: 1656192
[TBL] [Abstract][Full Text] [Related]
26. 5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils.
Wijkander J; O'Flaherty JT; Nixon AB; Wykle RL
J Biol Chem; 1995 Nov; 270(44):26543-9. PubMed ID: 7592874
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of chemotactic factor-stimulated neutrophil oxidative metabolism by leukotriene B4.
Gay JC; Beckman JK; Brash AR; Oates JA; Lukens JN
Blood; 1984 Oct; 64(4):780-5. PubMed ID: 6089934
[TBL] [Abstract][Full Text] [Related]
28. SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions.
Tsai BS; Villani-Price D; Keith RH; Zemaitis JM; Bauer RF; Leonard R; Djuric SW; Shone RL
Prostaglandins; 1989 Dec; 38(6):655-74. PubMed ID: 2561214
[TBL] [Abstract][Full Text] [Related]
29. Specific binding of leukotriene B4 to a receptor on human polymorphonuclear leukocytes.
Kreisle RA; Parker CW
J Exp Med; 1983 Feb; 157(2):628-41. PubMed ID: 6296265
[TBL] [Abstract][Full Text] [Related]
30. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.
Sperling RI; Benincaso AI; Anderson RJ; Coblyn JS; Austen KF; Weinblatt ME
Arthritis Rheum; 1992 Apr; 35(4):376-84. PubMed ID: 1314609
[TBL] [Abstract][Full Text] [Related]
31. The monocyte-derived neutrophil activating peptide (NAP/interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate.
Schröder JM
J Exp Med; 1989 Sep; 170(3):847-63. PubMed ID: 2549166
[TBL] [Abstract][Full Text] [Related]
32. Intracellular retention of the 5-lipoxygenase pathway product, leukotriene B4, by human neutrophils activated with unopsonized zymosan.
Williams JD; Lee TH; Lewis RA; Austen F
J Immunol; 1985 Apr; 134(4):2624-30. PubMed ID: 2982947
[TBL] [Abstract][Full Text] [Related]
33. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit.
Marleau S; Fruteau de Laclos B; Sanchez AB; Poubelle PE; Borgeat P
J Immunol; 1999 Sep; 163(6):3449-58. PubMed ID: 10477617
[TBL] [Abstract][Full Text] [Related]
34. Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils.
Betts WH; Hurst NP; Murphy GA; Cleland LG
Biochem Pharmacol; 1990 Apr; 39(7):1233-7. PubMed ID: 2157444
[TBL] [Abstract][Full Text] [Related]
35. Mediation of leukocyte components of inflammatory reactions by lipoxygenase products of arachidonic acid.
Goetzl EJ; Goldman DW; Naccache PH; Sha'afi RI; Pickett WC
Adv Prostaglandin Thromboxane Leukot Res; 1982; 9():273-82. PubMed ID: 6283846
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
[TBL] [Abstract][Full Text] [Related]
37. Depressed leukotriene B4 chemotactic response of neutrophils from localized juvenile periodontitis patients.
Offenbacher S; Scott SS; Odle BM; Wilson-Burrows C; Van Dyke TE
J Periodontol; 1987 Sep; 58(9):602-6. PubMed ID: 2821216
[TBL] [Abstract][Full Text] [Related]
38. The leukotriene B
Deng B; Lin Y; Ma S; Zheng Y; Yang X; Li B; Yu W; Xu Q; Liu T; Hao C; He R; Ding F
Kidney Int; 2017 Jul; 92(1):89-100. PubMed ID: 28318626
[TBL] [Abstract][Full Text] [Related]
39. Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage.
Martin TR; Raugi G; Merritt TL; Henderson WR
J Clin Invest; 1987 Oct; 80(4):1114-24. PubMed ID: 2821074
[TBL] [Abstract][Full Text] [Related]
40. A reevaluation of the chemotactic potency of leukotriene B4 (LTB4).
Jubiz W
Biochem Biophys Res Commun; 1983 Feb; 110(3):842-50. PubMed ID: 6301465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
